Profectus and Path Malaria Vaccine Initiative Enter Research Collaboration
Profectus BioSciences, Inc. (Baltimore, MD), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for serious chronic infections, has signed a research collaboration agreement with the PATH Malaria Vaccine Initiative (Bethesda, MD) to conduct proof-of-concept studies with its proprietary, recombinant vesicular stomatitis virus (rVSV) vector technology as a preventative malaria vaccine.
Profectus BioSciences, Inc. (Baltimore, MD), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for serious chronic infections, has signed a research collaboration agreement with the PATH Malaria Vaccine Initiative (Bethesda, MD) to conduct proof-of-concept studies with its proprietary, recombinant vesicular stomatitis virus (rVSV) vector technology as a preventative malaria vaccine.
Profectus has two key vaccine vector platforms, plasmid DNA and rVSV, which can be sequentially administered in a prime-boost regimen to elicit a potent and durable immune response to target pathogens. Each of these vectors alone is capable of inducing a strong immune response. Furthermore, when these vectors are sequentially used in a prime-boost regimen, immune responses of significantly greater magnitude and quality are generated. This approach represents a significant advancement in vaccine development as compared to historical DNA vaccines and adenovirus-based vectors.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
